Loading...
Loading...
MYMD| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 0.0K |
| Gross Profit | 0.0K |
| Operating Expense | 3,709.9K |
| Operating I/L | -3,709.9K |
| Other Income/Expense | 16.2K |
| Interest Income | 15.5K |
| Pretax | -3,693.7K |
| Income Tax Expense | -31.6K |
| Net Income/Loss | -3,662.1K |
MyMD Pharmaceuticals, Inc. is a clinical development stage pharmaceutical company specializing in therapeutic platforms. Their flagship product, MYMD-1, is a small molecule drug designed to regulate the immune system, targeting chronic inflammation and pro-inflammatory cytokines. Additionally, the company is developing Supera-CBD, a synthetic derivative of cannabidiol for chronic pain, addiction, and epilepsy treatment. With a focus on addressing autoimmune diseases and COVID-19-associated depression, MyMD Pharmaceuticals aims to generate revenue through the commercialization of these innovative drug platforms.
